Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Prone Positioning and Thoracoabdominal Binding on Lung and Muscle Protection in ARDS Patients During Spontaneous Breathing

23 septembre 2026 mis à jour par: Rodrigo Cornejo, University of Chile

Effect of Prone Positioning and Thoracoabdominal Binding on Lung and Muscle Protection in ARDS Patients With ICU-acquired Weakness Transitioning From Controlled to Spontaneous Breathing

Ventilator-induced diaphragmatic dysfunction and intensive care unit (ICU)-acquired weakness are two consequences of prolonged mechanical ventilation and critical illness in patients with acute respiratory distress syndrome (ARDS). Both complicate the process of withdrawing mechanical ventilation, increase hospital mortality and cause chronic disability in survivors. During transition from controlled to spontaneous breathing, these complications of critical illness favor an abnormal respiratory pattern and recruit accessory respiratory muscles which may promote additional lung and muscle injury. The type of ventilatory support and positioning may affect the muscle dysfunction and patient-self-inflicted lung injury at spontaneous breathing onset. In that regard, ARDS patients with ventilator-induced diaphragmatic dysfunction and ICU-acquired weakness who are transitioning from controlled to partial ventilatory support probably present an abnormal respiratory pattern which exacerbates lung and muscle injury. Physiological-oriented ventilatory approaches based on prone positioning or semi recumbent positioning with abdominal binding at spontaneous breathing onset, could decrease lung and muscle injury by favoring a better neuromuscular efficiency, and preventing intense inspiratory efforts and high transpulmonary driving pressures, as well as high-magnitude pendelluft. In the current project, in addition to perform a multimodal description of the severity of ventilator-induced diaphragmatic dysfunction and ICU-acquired weakness in prolonged mechanically ventilated ARDS patients, prone positioning and supine plus thoracoabdominal binding at spontaneous breathing onset will be evaluated.

Aperçu de l'étude

Description détaillée

The study was designed in three phases: a multimodal physiological description, a randomized crossover trial, and a pilot randomized trial. The multimodal physiological description and the randomized crossover trial were conducted in the same cohort. The pilot randomized trial was not conducted.

Multimodal Physiological Description Phase: a multimodal physiological description was performed to characterize ICU acquired weakness and ventilator-induced diaphragm dysfunction in prolonged mechanically ventilated ARDS patients at spontaneous breathing onset, in pressure support ventilation mode. The assessments included conventional electromyography (cEMG); electrical activity of the diaphragm; respiratory muscle ultrasound; respiratory flow; tidal volume; airway, esophageal and gastric pressures; and hemodynamic and electrical impedance tomography monitoring. Diaphragm ultrasound and cEMG were performed after the crossover trial, to avoid reducing PEEP and PS to the standardized low values required for diaphragm ultrasound (PEEP and PS of 6 cmH2O) before the crossover conditions, which could alter respiratory mechanics at protocol entry; cEMG findings were not expected to change over this timeframe (amendment approved by IRB No. 45/2024; May 15, 2024).

Randomized Crossover Trial Phase: Patients were asigened in random order to three 60-minute conditions on pressure support ventilation mode: A.- Control group: semi-recumbent position at 45º (previously described as supine at 45º), B.- Thoracoabdominal binding: semi-recumbent position at 45º plus thoracoabdominal binding, C.- Prone positioning (without thoracoabdominal binding). These strategies were performed under individualized PEEP (obtained at the lowest combination of collapse and overdistension according to electrical impedance tomography), with 15-minute washout periods of in assisted/controlled ventilation between conditions.

Pilot Randomized Trial Phase: This phase was designed to randomize patients to one of the three strategies under standard PEEP (ARDSNet strategy), with PET/CT imaging and biomarker analysis. The originally registered enrollment (n = 36) corresponded to this phase. A protocol amendment approved by the local ethics committee in May 2024 established that patients enrolled in this phase were not required to have completed the multimodal description and crossover phases, and reduced the planned sample size to 12 patients due to budgetary and logistical constraints. The phase was ultimately not conducted; the decision not to conduct it was reported to the local ethics committee and approved by the national funding agency.

Enrollment: The target enrollment for the crossover phase (24 patients) was established in the May 2024 protocol amendment. Recruitment was closed after 14 patients had been enrolled.

Type d'étude

Interventionnel

Inscription (Réel)

14

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Independencia, Chili
        • Hospital Clínico Universidad de Chile

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adult ARDS patients with moderate-severe ARDS on controlled protective mechanical ventilation for more than 2 days (modified from "more than 3 days" by the protocol amendment approved in May 2024)
  • Stable hemodynamics
  • Level of consciousness enough to initiate spontaneous breathing

Exclusion Criteria:

  • Unstable hemodynamics
  • Tracheostomy
  • Abnormal level of consciousness
  • Central nervous system injury
  • Esophageal varices
  • Pregnancy
  • Contraindications for installation of electrical impedance tomography or nasogastric catheter placement
  • Contraindications for prone positioning and thoracoabdominal binding
  • Chronic neuromuscular disorders
  • Obstructive lung disease; intrinsic positive end-expiratory pressure (PEEP) ≥3 cmH₂O (measured without inspiratory effort);
  • Recent-onset sepsis and moderate-to-severe metabolic acidosis;
  • Multi-organ failure with high short-term mortality risk
  • Clinical evidence of respiratory or hemodynamic instability

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Control Group

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in semi-recumbent position at 45º degrees, performed under individualized PEEP applied in random order.

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.

Expérimental: Prone Positioning

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in prone position, performed under individualized PEEP applied in random order.

Prone positioning will be performed according to ICU local protocol with trained provider teams.

Expérimental: Thoracoabdominal Binding

ARDS patients at spontaneous breathing onset on pressure support ventilation mode in semi-recumbent position at 45º degrees using thoracoabdominal binding with the binder's upper edge above the costal margin, performed under individualized PEEP applied in random order.

Thoracoabdominal binding will be used in semi-recumbent position (at 45º) and titrated to obtain a approximately 20% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
(Randomized Crossover Trial Phase) Pendelluft Magnitude
Délai: One hour on each ventilatory strategy

Pendelluft magnitude monitored by electrical impedance tomography, analyzed as a continuous variable. Title corrected in September 2026 from "High-Magnitude Pendelluft", as no threshold was prespecified and the sample size calculation was based on a continuous outcome, according to the protocol amendment approved in May 2024.

One hour on each ventilatory strategy
(Randomized Crossover Trial Phase) Neuromechanical Coupling of the Diaphragm
Délai: One hour on each ventilatory strategy

Ratio between transdiaphragmatic pressure and electrical activity of the diaphragm, measured by an esophageal/gastric catheter. Co-primary outcome with pendelluft magnitude. Prespecified as primary in the ethics-approved protocol and described in the Brief Summary and as a secondary outcome of the Pilot Randomized Trial Phase, but omitted in error from the Crossover Phase outcomes in the original registration. Added in September 2026.

One hour on each ventilatory strategy

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
(Randomized Crossover Trial Phase) Respiratory Mechanics Variables
Délai: One hour on each ventilatory strategy

Esophageal pressure swing, gastric pressure, transdiaphragmatic pressure and transpulmonary driving pressure measured by a esophageal/gastric catheter

One hour on each ventilatory strategy

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Rodrigo Cornejo, University of Chile

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

6 décembre 2023

Achèvement primaire (Réel)

28 août 2025

Achèvement de l'étude (Réel)

28 août 2025

Dates d'inscription aux études

Première soumission

6 mars 2023

Première soumission répondant aux critères de contrôle qualité

21 avril 2023

Première publication (Réel)

24 avril 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying the published results will be available upon reasonable request to the principal investigator, subject to approval by the local ethics committee and a data use agreement.

Délai de partage IPD

Beginning after publication, for 5 years.

Critères d'accès au partage IPD

Researchers with a methodologically sound proposal, after ethics committee approval.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner